World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
85
Citations
40864
World Ranking
1296
National Ranking
674

Medicine

D-Index
87
Citations
41418
World Ranking
13415
National Ranking
6821

Peter B. Gilbert publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Peter B. Gilbert sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 357 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Peter B. Gilbert D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Peter B. Gilbert sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 85 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2014 - Fellow of the American Statistical Association (ASA)

Overview

Peter B. Gilbert is affiliated with the Fred Hutchinson Cancer Research Center in the United States and has made significant contributions to medical research, particularly in infectious diseases and vaccine efficacy. Their work spans the fields of Medicine with a strong focus on Infectious Diseases, Statistics and Probability, Virology, Health, and Immunology.

Gilbert's research specialization includes key topics such as SARS-CoV-2 and COVID-19 research, HIV research and treatment, vaccine coverage and hesitancy, COVID-19 clinical research studies, HIV/AIDS drug development and treatment, statistical methods and inference, and advanced causal inference techniques.

Some of the notable recent papers authored or co-authored by Gilbert include:

  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial (2022, Science)
  • Evidence for antibody as a protective correlate for COVID-19 vaccines (2021, Vaccine)
  • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (2021, New England Journal of Medicine)
  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition (2021, New England Journal of Medicine)
  • Prospects for a safe COVID-19 vaccine (2020, Science Translational Medicine)

Frequent co-authors linked with Gilbert's research include:

  • Lawrence Corey
  • Yunda Huang
  • Lindsay N. Carpp
  • James G. Kublin
  • Dean Follmann

Gilbert frequently publishes in venues such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • arXiv (Cornell University)
  • Nature Communications
  • SSRN Electronic Journal

An award presented to Gilbert is the Fellowship of the American Statistical Association (ASA), received in 2014.

Best Publications

  • Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

    Lindsey R. Baden;Hana M El Sahly;Brandon J Essink;Karen Kotloff

  • Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

    Barton F. Haynes;Peter B. Gilbert;M. Juliana McElrath;Susan Zolla-Pazner

  • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

    Susan P Buchbinder;Devan V Mehrotra;Ann Duerr;Daniel W Fitzgerald

  • Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

    Ming Li;Feng Gao;John R. Mascola;Leonidas Stamatatos

  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

    Peter B Gilbert;Peter B Gilbert;David C Montefiori;Adrian B McDermott;Youyi Fong

  • Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

    Punnee Pitisuttithum;Peter Gilbert;Marc Gurwith;William Heyward

  • Evidence for antibody as a protective correlate for COVID-19 vaccines

    Kristen A. Earle;Donna M. Ambrosino;Andrew Fiore-Gartland;David Goldblatt

  • Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

    Saranya Sridhar;Alexander Luedtke;Edith Langevin;Ming Zhu

  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

    Michael S. Seaman;Holly Janes;Natalie Hawkins;Lauren E. Grandpre

  • Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna

  • Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana.

    Sheri Weiser;William Wolfe;William Wolfe;David Bangsberg;Ibou Thior

  • Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.

    Ibou Thior;Shahin Lockman;Laura M Smeaton;Roger L Shapiro

  • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

    Hana M El Sahly;Lindsey R Baden;Brandon Essink;Susanne Doblecki-Lewis

  • Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

    Morgane Rolland;Paul T. Edlefsen;Brendan B. Larsen;Sodsai Tovanabutra

  • Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

    Daniel E Neafsey;Michal Juraska;Trevor Bedford;David Benkeser

  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

    Nicole L. Yates;Nicole L. Yates;Hua Xin Liao;Hua Xin Liao;Youyi Fong;Allan DeCamp

  • Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial

    Peter B. Gilbert;Michael L. Peterson;Dean Follmann;Michael G. Hudgens

  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

    Lawrence Corey;Peter B Gilbert;Michal Juraska;David C Montefiori

  • Prevalence and predictive value of intermittent viremia with combination hiv therapy.

    Diane V. Havlir;Roland Bassett;Diane Levitan;Peter Gilbert

  • Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

    Mattia Bonsignori;Justin Pollara;M. Anthony Moody;Michael D. Alpert

  • Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

    Georgia D. Tomaras;Guido Ferrari;Xiaoying Shen;S. Munir Alam

Frequent Co-Authors

Lawrence Corey
Lawrence Corey Fred Hutchinson Cancer Research Center
M. Juliana McElrath
M. Juliana McElrath University of Washington
Georgia D. Tomaras
Georgia D. Tomaras Duke University
David C. Montefiori
David C. Montefiori Duke University
Nicole Frahm
Nicole Frahm Fred Hutchinson Cancer Research Center
Merlin L. Robb
Merlin L. Robb Walter Reed Army Institute of Research
Nelson L. Michael
Nelson L. Michael Walter Reed Army Institute of Research
Sorachai Nitayaphan
Sorachai Nitayaphan Armed Forces Research Institute of Medical Science
James G. Kublin
James G. Kublin Fred Hutchinson Cancer Research Center
Jerome H. Kim
Jerome H. Kim Walter Reed Army Institute of Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career opportunities. Many students start with foundational nursing programs before specializing. If you’re without a nursing background, exploring online nursing programs for non nurses is an excellent way to enter the field through flexible and accessible coursework.

For faster entry, several accelerated programs help students quickly gain credentials. Programs like accelerated fnp programs enable aspiring Family Nurse Practitioners to complete their education efficiently, combining rigorous training with online convenience.

Those seeking easier admissions or quicker paths might consider options like the easiest accelerated nursing programs to get into or even entry-level courses such as easy lpn programs to get into. These pathways allow learners to begin their nursing careers with accessible prerequisites and manageable program requirements, often leading to further specialization in healthcare fields related to Immunology.

Exploring these related degrees online provides flexibility and opens doors to vital roles supporting Immunology research, patient care, and public health initiatives across the USA.

Best Scientists Citing Peter B. Gilbert

Trending Scientists

Recently Published Articles